These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21391906)

  • 21. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies.
    Stühmer T; Bargou RC
    Cell Cycle; 2006 Jan; 5(1):39-42. PubMed ID: 16322696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
    Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
    Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.
    Polański R; Noon AP; Blaydes J; Phillips A; Rubbi CP; Parsons K; Vlatković N; Boyd MT
    Cancer Lett; 2014 Oct; 353(2):211-9. PubMed ID: 25067787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
    Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
    BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nutlin kills cancer cells via mitochondrial p53.
    Morselli E; Galluzzi L; Kepp O; Kroemer G
    Cell Cycle; 2009 Jun; 8(11):1647-8. PubMed ID: 19448434
    [No Abstract]   [Full Text] [Related]  

  • 29. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
    Gu L; Zhu N; Findley HW; Zhou M
    Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes.
    Arva NC; Talbott KE; Okoro DR; Brekman A; Qiu WG; Bargonetti J
    Ethn Dis; 2008; 18(2 Suppl 2):S2-1-8. PubMed ID: 18646312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
    Vaseva AV; Marchenko ND; Moll UM
    Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
    Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
    J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis.
    Bhattacharya S; Ray RM; Chaum E; Johnson DA; Johnson LR
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):3368-80. PubMed ID: 21345989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.
    Coll-Mulet L; Iglesias-Serret D; Santidrián AF; Cosialls AM; de Frias M; Castaño E; Campàs C; Barragán M; de Sevilla AF; Domingo A; Vassilev LT; Pons G; Gil J
    Blood; 2006 May; 107(10):4109-14. PubMed ID: 16439685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
    Millard M; Pathania D; Grande F; Xu S; Neamati N
    Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
    Di J; Zhang Y; Zheng J
    Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer.
    Van Maerken T; Rihani A; Van Goethem A; De Paepe A; Speleman F; Vandesompele J
    Cancer Lett; 2014 Mar; 344(2):157-65. PubMed ID: 24262662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.
    Chen L; Zhao Y; Halliday GC; Berry P; Rousseau RF; Middleton SA; Nichols GL; Del Bello F; Piergentili A; Newell DR; Lunec J; Tweddle DA
    Br J Cancer; 2014 Aug; 111(4):716-25. PubMed ID: 24921920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.